tirzepatide mounjaro for weight loss FDA approves new version of diabetes drug to be sold Mounjaro 2.5 mg Tirzepatide injection

Jul 30 2013;93(2-3):69-77

The Danish company's semaglutide patent is expiring in China far ahead of its expiry in key markets such as Japan, Europe and the U.S

However, there is a catch worth knowing about

Key Takeaways GLP-1 medications can cause dizziness by altering fluid balance and increasing sodium loss through the kidneys, leading to temporary drops in blood pressure when standing

The clinical payoff of this dual mechanism was established in the SURMOUNT-1 trial, a phase 3 randomized, double-blind, placebo-controlled study of 2,539 adults with obesity or overweight without diabetes

These require a bit more caution for individuals on semaglutide, especially those who also have type 2 diabetes